Search results for #ASCO23
@TumorBoardTues @DrGattiMays @IntegrityCE @PTarantinoMD @Dr_RShatsky @ErikaHamilton9 @CharuAggarwalMD @dradityabardia @hoperugo @maryam_lustberg @drteplinsky @DrSGraff @jane_meisel @JenniferLitton @drsarahsam @IlanaSchlam @nlinmd @YAbdouMD @ArielleMedford @laura_huppert @drivorymd @hmcarthur 22/28 Tweetorial #17 #TumorBoardTuesday 🤨Optimal ADC sequencing 🔀 is unknown #QuestionsUnanswered ⁉️ 🤓Real world data of efficacy of sequential ADCs is needed ‼️ 🤩Ableman presented small study at #ASCO23: ADC☝️ > ADC✌️
What Do Key Opinion Leaders in Lung Cancer Think of the Latest Clinical Trial Data? #lcsm Data from #ASCO23 #ELCC24 and @IASLC Meetings 👉Organized KOL Sentiment Analyses on Top Trials in Lung Cancer ADAURA: beta.kolpulse.com/public/1409290… APPLE: beta.kolpulse.com/public/1409290… CHECKMATE 816:…
Dr. @JavierCortesMD presented the #PHERGain 3-year disease-free survival results at #ASCO23 and, following @TheLancet publication, emphasized the achievements attained in this study. Learn more about the study: medsir.org/post/revolutio… #MEDSIRtheLancet #OncologyResearch
Thanks for quoting me @fsabino_onco! Agree, Gr8 data shared by @ArndtVogel from @annemariamay @JNCI_Now Survival curves are interesting Exercise promissing on ICI-AEs! Aligned w our data from the ExIO study at #ASCO23 Maybe more to come at #ASCO24 😉 meetings.asco.org/abstracts-pres…
Thanks for quoting me @fsabino_onco! Agree, Gr8 data shared by @ArndtVogel from @annemariamay @JNCI_Now Survival curves are interesting Exercise promissing on ICI-AEs! Aligned w our data from the ExIO study at #ASCO23 Maybe more to come at #ASCO24 😉 meetings.asco.org/abstracts-pres… https://t.co/RkUYSSkzJV
Agree with amazing @montypal such a huge effort by many! Honored to have presented NGS data #asco23 poster discussion with @shilpaonc Thanks to patients, PIs: Monty & @siadaneshmand & all co-Is! Great to work with my colleague @spsutkaMD et al. @uwurology @fredhutch to accrue!
Agree with amazing @montypal such a huge effort by many! Honored to have presented NGS data #asco23 poster discussion with @shilpaonc Thanks to patients, PIs: Monty & @siadaneshmand & all co-Is! Great to work with my colleague @spsutkaMD et al. @uwurology @fredhutch to accrue!
FYI: Energy drink consumption was highlighted in an #ASCO23 research presentation from Dr. Eric Lander, Vanderbilt University re Early Onset CRC @CathyEngMD @
It's ultimately going to be prevention studies like this that "end cancer as we know it". Presented at #ASCO23.
Germline alterations in patients with lung cancer [2023] Govindan et al. #ASCO23 Abst 10512 meetings.asco.org/abstracts-pres… #lcsm #geneticcounselors @WUSTLmed @TempusLabs
Investigation into aberrant B cell repertoire in myeloma on humoral immunity and patient survival [May 31, 2023] @LBP0818 et al. #ASCO23 Abstract 8016 ascopubs.org/doi/abs/10.120… #mmsm #IDonc #ImmunoOnc
Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial | Journal of Clinical Oncology Simple solutions to seemingly complex problems👇 @JCO_ASCO #ASCO23 ascopubs.org/doi/10.1200/JC…
@_ShankarSiva @FordePatrick @jryckman3 @AcceleratorsRO @DrewMoghanaki @bensolomon1 @BrendonStilesMD This is something that we will have to discuss closely. There is tox from treatment and financial tox but is this trumped by being disease free? See @bensolomon1 excellent #ASCO23 discussion slide
Also a 20 Aug 2024 Pdufa date for Servier's vorasidenib in IDH-mutant diffuse glioma (Indigo trial). I wonder if the probable cases of Hy's law will be a review issue, per #ASCO23 discussion.
Seems relevant to resurface Dr Andrew Ko’s observation at #asco23 that orders of magnitude separate the cost of NALIRIFOX vs FOLFIRINOX ‼️
Seems relevant to resurface Dr Andrew Ko’s observation at #asco23 that orders of magnitude separate the cost of NALIRIFOX vs FOLFIRINOX ‼️ https://t.co/8tjEe9C4Ds
What happened to $NVCR in 2023? Follow the LUNAR Trial Discussion by KOLs at #ASCO23 👉beta.kolpulse.com/public/1409290… Key Thoughts by @StephenVLiu @Timothee_MD @Latinamd @DrSanjayPopat
Dr Mark Kris discusses conversations from ASCO 2023 that may affect the care of patients with lung cancers. #LungCancer #ASCO23 ms.spr.ly/6016i7Fai
Dr Mark Kris discusses conversations from #ASCO23 that may affect the care of patients with lung cancers. #LungCancer ms.spr.ly/6019i7FID
📍Clinical Data Part-5 ● Combination of BRAF + MEK inhibitors Encorafenib + Binimetinib Phase 2 PHAROS study #ASCO23 #9018
T cell exhaustion markers in multiple myeloma patients before and after physical activity intervention - Joseph et al. #ASCO23 Abstract 8060 meetings.asco.org/abstracts-pres… #mmsm #ImmunoOnc HT @RahulBanerjeeMD
JUST IN: @US_FDA approved erdafitinib for metastatic urothelial carcinoma (mUC) w/FGFR3 alterations, post 1 line TX. Approval based on THOR trial in @NEJM; led by @y_loriot @GustaveRoussy & #siefkerRadtke @MDAndersonNews presented #ASCO23 @ASCO nejm.org/doi/full/10.10… Link:…
allassana sylla @asco23
2 Followers 0 Following
Hematology & Oncology.. @HemOncWomenDocs
6K Followers 1K Following #HOWPG is a worldwide network of 2200+ women physicians practicing #oncology. #HemeOncWolfpack #SheForShe #WomenInMedicine #ASCO23